Clinical trial
Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic…
NCT00429858 · Andrew Ko, Other · Terminated
Key facts
| NCT number | NCT00429858 |
|---|---|
| Title | Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer |
| Official title | Individualized Management of Pancreatic Cancer With Targeted Therapeutics (IMPACTT): A Phase II Clinical Trial |
| Lead sponsor | Andrew Ko, Other |
| Collaborators | Eli Lilly and Company Industry Taiho Pharmaceutical Co., Ltd. |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | S-1, gemcitabine hydrochloride |
| Enrollment | 21 |
| Start date | Jan 22, 2007 |
| Primary completion | Jan 20, 2010 |
| Completion | Jan 20, 2010 |
| First posted | Feb 1, 2007 |
| Last update posted | Sep 18, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: